drugset / Trial / NCT01884350

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)

NCT01884350

Phase 4 Completed 1217 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelOther

Summary

The study purpose is to assess the impact of an educational program on patient adherence in patients taking Apixaban for SPAF at 24 weeks

Timeline

Start
2013-10-15
Primary completion
2016-01-20
Completion
2016-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 2.5 mg Oral
Subject Apixaban Small molecule 5 mg Oral

Indications